An overview of the lower cretaceous dinosaur tracksites from the mirambel formation in the iberian range (ne spain)

Up to now, the ichnological vertebrate record from the Barremian Mirambel Formation (NE Spain) has remained completely unknown despite the fact that osteological findings have been reported in recent years. Here we provide an overview of 11 new dinosaur tracksites found during a fieldwork campaign in the year 2011. The majority of these tracksites (seven) preserve small- to medium-sized tridactyl tracks here assigned to indeterminate theropods. Only one footprint presents enough characters to classify it as Megalosauripus isp. Ornithopod tracks identified as Caririchnium isp. and Iguanodontipodidae indet. and sauropod tracks are recorded at two tracksites. The footprints are preserved in a variety of paleoenvironmental conditions and thus display different kinds of preservation (true tracks, shallow undertracks, natural casts and undertrack casts). The ichnological record from the Mirambel Formation seems to be theropod dominated. This is a clear discrepancy with the osteological record identified in this formation, which shows a predominance of ornithopod dinosaurs

Benzotriazolium picrate

In the crystal structure of the title compound, C6H6N3 +·C6H2N3O7 −, anions and cations are linked into chains along [010] by inter­molecular N—H⋯O hydrogen bonds. These chains are further stabilized by weak C—H⋯O hydrogen bonds and π–π stacking inter­actions with a centroid–centroid distance of 3.908 (1) Å

Orobanche centaurina Bertol. the correct name for O. kochii F.W. Schultz (Orobanchaceae)

Después de estudiar el material original de Orobanche centaurina Bertol. (Orobanchaceae) depositado en BOLO, una olvidada especie descrita de Massa (Italia central) parásita de Centaurea paniculata L., y compararlo con el tipo de O. kochii F.W. Schultz y con los tipos de otros táxones actualmente considerados inónimos de éste, estimamos que el nombre de Bertoloni es el correcto y prioritario para esta especi

The First Korean Case of Cutaneous Lung Tissue Heterotopia

Cutaneous lung tissue heterotopia is a very rare disorder where mature lung tissues develop in the skin. This is only the second known report of cutaneous lung tissue heterotopia, with the first by Singer et al. in 1998. A newborn infant had a hemangioma-like, freely movable mass connected to the anterior aspect of the sternal manubrium. Pathologic findings showed mature lung tissues with bronchi, bronchioles, and alveoli through the dermis and subcutis, and it was diagnosed as cutaneous lung tissue heterotopia. Cutaneous lung tissue heterotopia is hypervascular, so grossly it looks like a hemangioma. It can be differentiated from pulmonary sequestration, teratoma, bronchogenic cyst, and branchial cleft cyst by histology and the location of the mass. We describe the clinical, radiologic, and pathologic findings of a cutaneous lung tissue heterotopia, the first reported in Korea

The genetics of cardiovascular disease

Recent advances in genotyping technology and insights into disease mechanisms have increased interest in the genetics of cardiovascular disease. Several candidate genes involved in cardiovascular diseases were identified from studies using animal models, and the translation of these findings to human disease is an exciting challenge. There is a trend towards large-scale genome-wide association studies that are subject to strict quality criteria with regard to both genotyping and phenotyping. Here, we review some of the strategies that have been developed to translate findings from experimental models to human disease and outline the need for optimizing global approaches to analyze such results. Findings from ongoing studies are interpreted in the context of disease pathways instead of the more traditional focus on single genetic variants

Direct-acting antivirals are effective and safe in HCV/HIV-coinfected liver transplant recipients who experience recurrence of hepatitis C: A prospective nationwide cohort study.

Direct-acting antivirals have proved to be highly efficacious and safe in monoinfected liver transplant (LT) recipients who experience recurrence of hepatitis C virus (HCV) infection. However, there is a lack of data on effectiveness and tolerability of these regimens in HCV/HIV-coinfected patients who experience recurrence of HCV infection after LT. In this prospective, multicenter cohort study, the outcomes of 47 HCV/HIV-coinfected LT patients who received DAA therapy (with or without ribavirin [RBV]) were compared with those of a matched cohort of 148 HCV-monoinfected LT recipients who received similar treatment. Baseline characteristics were similar in both groups. HCV/HIV-coinfected patients had a median (IQR) CD4 T-cell count of 366 (256-467) cells/µL. HIV-RNA was <50 copies/mL in 96% of patients. The DAA regimens administered were SOF + LDV ± RBV (34%), SOF + SMV ± RBV (31%), SOF + DCV ± RBV (27%), SMV + DCV ± RBV (5%), and 3D (3%), with no differences between the groups. Treatment was well tolerated in both groups. Rates of SVR (negative serum HCV-RNA at 12 weeks after the end of treatment) were high and similar for coinfected and monoinfected patients (95% and 94%, respectively; P = .239). Albeit not significant, a trend toward lower SVR rates among patients with advanced fibrosis (P = .093) and genotype 4 (P = .088) was observed. In conclusion, interferon-free regimens with DAAs for post-LT recurrence of HCV infection in HIV-infected individuals were highly effective and well tolerated, with results comparable to those of HCV-monoinfected patients